Empagliflozin 25 mg (DrugBank: Empagliflozin)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
72 | 下垂体性ADH分泌異常症 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04447911 (ClinicalTrials.gov) | January 2021 | 10/6/2020 | Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia | Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia - a Monocentric Randomized Double-blind Placebo-controlled Trial (the EMPOWER Study) | Hyponatremia;SIADH;Liver Failure;Kidney Failure | Drug: Empagliflozin 25 MG;Drug: Placebo | University Hospital, Basel, Switzerland | NULL | Not yet recruiting | 18 Years | N/A | All | 172 | Phase 4 | NULL |